GENZ, Ilex acquisition delayed

Genzyme (GENZ) said its planned acquisition of ILXO is now expected to close in the fourth quarter instead of around mid-year as previously expected. GENZ said the delay is due to discussions with the Federal Trade Commission (FTC) about "outstanding issues regarding a proposed consent decree" for certain solid organ transplant applications of ILXO's cancer drug Campath alemtuzumab. ...